🚀 Medial Secures Investment on Shark Tank India - Fueling the Future of Professional Social Networking. 🔥
Login

News on Medial

Related News

Elevation Capital trims Ixigo stake, clocks 25X return

EntrackrEntrackr · 5m ago
Elevation Capital trims Ixigo stake, clocks 25X return
Medial

Elevation Capital trims Ixigo stake, clocks 25X return Elevation Capital (formerly SAIF Partners) has offloaded 21.5 lakh shares in Le Travenues Technology Ltd, the parent company of travel tech firm Ixigo, for Rs 38.27 crore (around $4.5 million). The partial exit marks a nearly 25X return on its investment. According to a disclosure on the Bombay Stock Exchange (BSE), SAIF Partners sold 21.5 lakh equity shares at Rs 178 each through block deals. This marks Elevation’s third partial exit from Ixigo. The VC firm had earlier sold shares worth Rs 100 crore ($12 million) in a pre-IPO secondary transaction, followed by a Rs 180 crore ($21 million) sell-off during the IPO via the offer-for-sale (OFS) route, together delivering estimated returns of 13X. As of March 31, 2025, Elevation held around 14.2% in Ixigo, down sharply from 23.4% in February 2024. The sell-off comes at a time when Ixigo reported a 72% year-on-year jump in revenue to Rs 284 crore in Q4 FY25, while its profit rose 2.4X to Rs 17 crore. For the full fiscal year (FY25), the company posted Rs 914 crore in revenue. At the close of today’s trading session (Tuesday, May 19), Ixigo’s shares were priced at Rs 174.6 each, with a total market capitalization of Rs 6,811 crore (approximately $800 million).

Schroder Fund enters Ixigo via Elevation stake acquisition

EntrackrEntrackr · 4m ago
Schroder Fund enters Ixigo via Elevation stake acquisition
Medial

Schroder Fund enters Ixigo via Elevation stake acquisition Elevation Capital (formerly SAIF Partners) sold Rs 135 crore ($15.7 million) worth of shares in Ixigo parent Le Travenues Technology via block deals on Thursday. This partial exit is estimated to have delivered a 25X return on investment for the venture capital firm. According to a filing accessed from the Bombay Stock Exchange (BSE), Elevation Capital offloaded 75.48 lakh shares at an average price of Rs 179.25 apiece. At the same time, global investor Schroder Fund made its entry into Ixigo by acquiring 53.68 lakh shares worth Rs 96.8 crore. Schroder Fund is a British multinational asset management firm with a presence in 37 locations across Europe, the Americas, the Middle East, and Africa. At present, it reportedly manages assets worth around $950 billion. Notably, the fund holds significant investments in Indian companies, particularly HDFC Bank and ICICI Bank, which together make up around 6–7% of its total portfolio. In the startup space, Schroder is one of the largest stakeholders in e-commerce-focused packaging company Bizongo and also participated in Agrostar’s $70 million Series D round. It has also backed Lenskart, FirstCry, Cultfit, Peel Works and Miko, among others. As of FY25, Elevation Capital held 5.46 crore shares in Ixigo (14.02%). After the partial sale, its stake will drop to 12.08%. This records Elevation’s fourth partial exit from Ixigo. Most recently, it sold 21.5 lakh shares for Rs 38.27 crore (about $4.5 million). Earlier, the firm had offloaded shares worth Rs 100 crore ($12 million) in a pre-IPO secondary deal and Rs 180 crore ($21 million) during the IPO. For the quarter ended March 2025, Ixigo reported a 72% year-on-year increase in revenue to Rs 284 crore, while profit rose 2.4X to Rs 17 crore. Its revenue grew 39% to Rs 914 crore, but net profit fell 18% to Rs 60.2 crore in FY25. At the close of trading on Thursday (June 19), Ixigo’s shares were priced at Rs 175, giving the company a market capitalization of Rs 6,885 crore.

Ixigo grants over 2 lakh ESOPs worth Rs 3.78 Cr

EntrackrEntrackr · 3m ago
Ixigo grants over 2 lakh ESOPs worth Rs 3.78 Cr
Medial

Ixigo grants over 2 lakh ESOPs worth Rs 3.78 Cr Le Travenues Technology Limited, the parent company of travel tech platform Ixigo, has granted 211,912 stock options under its ESOP schemes of ESOS 2013, 2020, 2021, and 2024. The options have been issued at an exercise price of Rs 93 per share and will vest over four years in equal annual tranches. At the current market price of Rs 178.6 per share, the total value of the grant stands at approximately Rs 3.78 crore, implying a per-option value gain of Rs 85.6 for eligible employees. Ixigo reported a 72% growth in scale in the last quarter of FY25, reporting a revenue of Rs 284 crore in Q4 FY25. Meanwhile, its year-on-year (YoY) profits increased by 2.4X to Rs 17 crore during the same period. Recently, Elevation Capital also offloaded 75.48 lakh shares of Ixigo at an average price of Rs 179.25 apiece. At the same time, global investor Schroder Fund made its entry into Ixigo by acquiring 53.68 lakh shares worth Rs 96.8 crore. At the close of trading on Wednesday (July 16), Ixigo’s shares were priced at Rs 179.8, giving the company a market capitalization of Rs 7,017 crore (approximately $820 million).

Schroders increases stake in Ixigo to 7.18%

EntrackrEntrackr · 1m ago
Schroders increases stake in Ixigo to 7.18%
Medial

Schroders increases stake in Ixigo to 7.18% Global asset manager Schroder Investment Management has increased its stake in Le Travenues Technology Limited, the parent of travel booking platform ixigo. According to a stock exchange filing, Schroders Group entities, acting as discretionary fund managers, acquired additional shares on September 18, 2025. The acquisition was made via the open market in which Schroders bought 41,638 shares of ixigo, increasing its stake by 0.011% to 7.179% from the previous holding of 7.169%. Schroders now has 2,80,28,378 shares of Ixigo. Earlier this year, Elevation Capital offloaded shares worth over Rs 226 crore in a bulk stake sale, realizing a return of approximately 31.6X on its investment. Meanwhile, in that same period, Schroders had picked up an additional 16.6 lakh shares from the open market, pushing its shareholding to 5.176%. Ixigo’s revenue from operations surged 72.5% to Rs 314 crore in Q1 FY26 compared to Rs 182 crore in Q1 FY25. During the period, the company’s net profit grew 27% year-on-year to Rs 19 crore in Q1 FY26 from Rs 15 crore in Q1 FY25. Ixigo’s shares are trading at Rs 278.55 (as of 15:31 PM), giving the online travel aggregator a market capitalization of Rs 10,874 crore.

Docon offloads 10% stake in Thyrocare for Rs 668 Cr

EntrackrEntrackr · 16d ago
Docon offloads 10% stake in Thyrocare for Rs 668 Cr
Medial

Docon Technologies Pvt Ltd, a promoter entity of Thyrocare Technologies, has sold 53.33 lakh equity shares representing around 10% of the company’s total paid-up capital through open market transactions on October 24, 2025. The sale was valued at Rs 667.7 crore at an average price of Rs 1,252 per share, according to a stock exchange filing. Following the transaction, Docon’s shareholding in Thyrocare has come down from 71% to 61% and continues to remain a promoter of the diagnostics chain with 3.2 crore shares. The block sale saw strong participation from domestic mutual funds. Among the key buyers were ICICI Prudential Mutual Fund, which purchased 17.49 lakh shares worth Rs 218.9 crore, and Aditya Birla Sun Life Mutual Fund, which picked up 10.33 lakh shares for Rs 129.3 crore. Other prominent investors included HSBC Mutual Fund Midcap Fund (6.66 lakh shares for Rs 83.4 crore), HDFC Mutual Fund (4.44 lakh shares for Rs 55.5 crore), and Eastspring Investments India Consumer Equity Open Limited (3.19 lakh shares for Rs 40 crore). The stake sale comes on the back of leadership transition within the PharmEasy-Thyrocare group. In August 2025, PharmEasy’s co-founder and CEO Siddharth Shah stepped down from his executive role to become the company’s Vice Chairman, while Thyrocare’s chief Rahul Guha was elevated as the new MD and CEO of API Holdings, the parent entity of PharmEasy and Thyrocare. Guha continues to lead Thyrocare alongside his expanded responsibilities at API. Thyrocare recently announced its financial numbers for the second quarter of the ongoing fiscal year FY26, posting a strong performance in the quarter. The company’s revenue from operations grew 22% year-on-year (YoY) to Rs 216.5 crore in Q2 FY26 from Rs 177.36 crore in Q2 FY25. Thyrocare’s profit jumped 81% YoY to Rs 47.9 crore in Q2 FY26, compared to Rs 26.4 crore in the corresponding quarter last year. For the first half of FY26, the company recorded a net profit that grew 71% to Rs 86.1 crore from Rs 50.4 crore in H1 FY25.

Download the medial app to read full posts, comements and news.